Other Legacy products — Total Revenues
Bristol-Myers Squibb Other Legacy products — Total Revenues decreased by 21.6% to $156M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 21.6%, from $199M to $156M. Over 3 years (FY 2022 to FY 2025), Other Legacy products — Total Revenues shows a downward trend with a -11.8% CAGR.
Analysis
How to read this metric
A decrease in revenue is expected as products age and lose patent exclusivity, while a sudden increase might indicate successful lifecycle management or temporary market dynamics. A rapid decline may signal a need for faster innovation to offset the loss of legacy cash flows.
Detailed definition
This metric represents the aggregate revenue generated from the company's portfolio of mature pharmaceutical products th...
Peer comparison
Peers in the pharmaceutical industry typically report this as 'Established Brands' or 'Mature Products' revenue, which is generally expected to decline over time as a percentage of total sales.
bmy_segment_other_legacy_products_total_revenuesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $290.5M | $290.5M | $290.5M | $290.5M | $246M | $248M | $237M | $231M | $228M | $222M | $225M | $250M | $199M | $223M | $177M | $199M | $156M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -15.3% | +0.8% | -4.4% | -2.5% | -1.3% | -2.6% | +1.4% | +11.1% | -20.4% | +12.1% | -20.6% | +12.4% | -21.6% |
| YoY Change | — | — | — | — | -15.3% | -14.6% | -18.4% | -20.5% | -7.3% | -10.5% | -5.1% | +8.2% | -12.7% | +0.5% | -21.3% | -20.4% | -21.6% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's other legacy products — total revenues?
- Bristol-Myers Squibb (BMY) reported other legacy products — total revenues of $156M in Q1 2026.
- How has Bristol-Myers Squibb's other legacy products — total revenues changed year-over-year?
- Bristol-Myers Squibb's other legacy products — total revenues decreased by 21.6% year-over-year, from $199M to $156M.
- What is the long-term trend for Bristol-Myers Squibb's other legacy products — total revenues?
- Over 3 years (2022 to 2025), Bristol-Myers Squibb's other legacy products — total revenues has grown at a -11.8% compound annual growth rate (CAGR), from $1.16B to $798M.
- What does other legacy products — total revenues mean?
- Total sales generated from older, mature pharmaceutical products that are no longer the primary growth drivers for the company.